Peter Welford
Stock Analyst at Jefferies
(1.36)
# 2,212
Out of 4,502 analysts
10
Total ratings
100%
Success rate
1.69%
Average return
Main Sectors:
Top Industries:
5 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Maintains: Buy | $121 → $123 | $109.93 | +11.43% | 1 | Jul 2, 2024 | |
| GSK GSK | Maintains: Buy | $53 → $53 | $39.07 | +35.65% | 2 | Jul 2, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $78.52 | - | 4 | Jan 3, 2024 | |
| GLPG Galapagos NV | Upgrades: Hold | $49 → $47 | $27.39 | +72.33% | 2 | Jan 23, 2023 | |
| GMAB Genmab | Downgrades: Hold | n/a | $28.13 | - | 1 | Sep 16, 2021 |
Novartis AG
Jul 2, 2024
Maintains: Buy
Price Target: $121 → $123
Current: $109.93
Upside: +11.43%
GSK
Jul 2, 2024
Maintains: Buy
Price Target: $53 → $53
Current: $39.07
Upside: +35.65%
AstraZeneca
Jan 3, 2024
Downgrades: Hold
Price Target: n/a
Current: $78.52
Upside: -
Galapagos NV
Jan 23, 2023
Upgrades: Hold
Price Target: $49 → $47
Current: $27.39
Upside: +72.33%
Genmab
Sep 16, 2021
Downgrades: Hold
Price Target: n/a
Current: $28.13
Upside: -